Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
This resource contains healthcare economic information exclusively for US Payer Formulary Committees or other similar entities who make decisions regarding pricing and formulary availability. Payer Formulary Committees or other similar entities refers to groups of individuals that evaluate pharmaceuticals to determine access to, and/or cost to access, a pharmaceutical product or treatment for patients in a health care system, for making decisions regarding pricing and formulary availability only. This information is not for use by medical professionals in a medical practice setting.
©2024 Takeda Pharmeceuticals U.S.A., Inc. 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved.TAKEDA and TAKHZYRO is a registered trademark of Dyax Corp.
are registered trademarks of Takeda Pharmaceutical Company Limited.